Pharmaceuticals

Global Psoriasis Biosimilars Market Forecast 2026–2035: Long-Term Growth Insights

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the psoriasis biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Psoriasis Biosimilars Market in 2026, and what figure is it projected to hit by 2030?

The psoriasis biosimilars market size has experienced rapid growth in recent years. It is anticipated to expand from $8.16 billion in 2025 to $9.08 billion in 2026, at a compound annual growth rate (CAGR) of 11.3%. The market’s historical growth can be attributed to the high cost of reference biologics, limited patient access to treatment options, the increasing prevalence of moderate to severe psoriasis, growing physician awareness and subsequent prescriptions, and the initial approvals of TNF-alpha inhibitors.

The psoriasis biosimilars market size is anticipated to undergo rapid expansion in the upcoming years. It is forecast to grow to $13.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is attributed to the launch of new biosimilars for infliximab, etanercept, and adalimumab, the expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, a rising adoption of patient assistance programs, and growth in clinical trials for novel biosimilars. Significant trends expected in the forecast period include the increasing adoption of cost-effective psoriasis biosimilars, a greater focus on patient access and affordability, the growth in subcutaneous and intravenous administration routes, the expansion of hospital and retail pharmacy distribution channels, and the development of targeted therapies for different psoriasis types.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

Which Drivers Are Affecting Market Participation In The Psoriasis Biosimilars Market?

The increasing detection rates of psoriatic arthritis are projected to drive the growth of the psoriasis biosimilars market moving forward. Psoriatic arthritis is a chronic autoimmune condition that results in inflammation of the joints and skin, frequently affecting individuals with a history of psoriasis. The diagnosis rates for psoriatic arthritis are on an upward trend, particularly due to enhanced screening protocols among individuals with psoriasis, which facilitate earlier and more accurate diagnosis by identifying subtle joint symptoms that might have previously been overlooked. Psoriasis biosimilars aid in managing psoriatic arthritis by offering affordable alternatives to biologic therapies, thereby effectively reducing joint inflammation and skin symptoms. For instance, in August 2025, according to the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, psoriatic arthritis impacts roughly 1 in 3 people living with psoriasis, and as many as 2.4 million Americans live with psoriatic arthritis, while more than 15% of people with psoriasis may also have undiagnosed psoriatic arthritis, highlighting both its increasing recognition and persistent underdiagnosis. Consequently, the rising psoriatic arthritis diagnosis rates are fueling the expansion of the psoriasis biosimilars market.

What Segment Classifications Make Up The Psoriasis Biosimilars Market?

The psoriasis biosimilars market covered in this report is segmented –

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

Which Trends Are Shaping Activity Within The Psoriasis Biosimilars Market?

Leading companies in the psoriasis biosimilars market are concentrating on introducing advanced solutions, such as biosimilars for plaque psoriasis, to improve access to treatment, lower healthcare costs, and enhance patient outcomes. Biosimilars for plaque psoriasis offer more affordable, highly similar alternatives to approved biologic drugs prescribed for this chronic autoimmune skin condition, which manifests as red, scaly patches. For example, in May 2025, Sandoz Group AG, a Switzerland-based firm specializing in generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, which is the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for use in adults with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, as well as pediatric patients aged six years and older (weighing over 60 kg) suffering from plaque psoriasis. This autoinjector is engineered to boost patient adherence and quality of life, offering precise automatic dosing, reduced injection discomfort, a compact design, and adaptable storage options for easier self-administration.

Which Major Industry Participants Are Leading The Psoriasis Biosimilars Market Growth?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Psoriasis Biosimilars Market?

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Psoriasis Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp

Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2026, By The Business Research Company

Connected Rail Market Report 2026

https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report

Rail Road Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/rail-road-construction-global-market-report

Freight Railcar Parts Market Report 2026

https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795